GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Buyback Yield %

LSB (LakeShore Biopharma Co) Buyback Yield % : 0.00 (As of Mar. 29, 2025)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

LakeShore Biopharma Co's current buyback yield was 0.00%.

LakeShore Biopharma Co Buyback Yield % Historical Data

The historical data trend for LakeShore Biopharma Co's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Buyback Yield % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Buyback Yield %
- - - -28.82

LakeShore Biopharma Co Quarterly Data
Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -28.82 -

Competitive Comparison of LakeShore Biopharma Co's Buyback Yield %

For the Biotechnology subindustry, LakeShore Biopharma Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Buyback Yield % falls into.


;
;

LakeShore Biopharma Co Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

LakeShore Biopharma Co's Buyback Yield for the fiscal year that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 39.463) / 136.946577
=-28.82%

LakeShore Biopharma Co's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 130.13242
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

LakeShore Biopharma Co Buyback Yield % Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Buyback Yield %
Comparable Companies
ABP DYAI ANVS BOLD OVID GRCE FBLG KZR ATRA GBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
H6Z0:Germany
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
Website
https://www.lakeshorebio.com
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.